88PRun-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. (17th December 2018) - Quiroga, V; Holgado, E; Alonso, J L; Andres, R; Moreno Anton, F; Alamo De La Gala, M D C; Henao, F; Cirauqui Cirauqui, B; Margeli, M; Cortes Castan, J; Gion Cortes, M; Soto, A; et al.